Combining serological and contact data to derive target immunity levels for achieving and maintaining measles elimination.
Adolescent
Adult
Child
Child, Preschool
Contact Tracing
/ statistics & numerical data
Disease Eradication
/ methods
Disease Outbreaks
/ prevention & control
Female
Geography
Health Services Needs and Demand
/ statistics & numerical data
Humans
Immunity, Herd
/ physiology
Incidence
Infant
Infant, Newborn
Male
Measles
/ epidemiology
Measles Vaccine
/ therapeutic use
Measles virus
/ immunology
Models, Statistical
Seroepidemiologic Studies
Vaccination
/ statistics & numerical data
Young Adult
Contacts
Elimination
Immunisation
Measles
Modelling
Social mixing
Threshold
Vaccination
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
25 09 2019
25 09 2019
Historique:
received:
11
04
2019
accepted:
20
08
2019
entrez:
26
9
2019
pubmed:
26
9
2019
medline:
15
1
2020
Statut:
epublish
Résumé
Vaccination has reduced the global incidence of measles to the lowest rates in history. However, local interruption of measles virus transmission requires sustained high levels of population immunity that can be challenging to achieve and maintain. The herd immunity threshold for measles is typically stipulated at 90-95%. This figure does not easily translate into age-specific immunity levels required to interrupt transmission. Previous estimates of such levels were based on speculative contact patterns based on historical data from high-income countries. The aim of this study was to determine age-specific immunity levels that would ensure elimination of measles when taking into account empirically observed contact patterns. We combined estimated immunity levels from serological data in 17 countries with studies of age-specific mixing patterns to derive contact-adjusted immunity levels. We then compared these to case data from the 10 years following the seroprevalence studies to establish a contact-adjusted immunity threshold for elimination. We lastly combined a range of hypothetical immunity profiles with contact data from a wide range of socioeconomic and demographic settings to determine whether they would be sufficient for elimination. We found that contact-adjusted immunity levels were able to predict whether countries would experience outbreaks in the decade following the serological studies in about 70% of countries. The corresponding threshold level of contact-adjusted immunity was found to be 93%, corresponding to an average basic reproduction number of approximately 14. Testing different scenarios of immunity with this threshold level using contact studies from around the world, we found that 95% immunity would have to be achieved by the age of five and maintained across older age groups to guarantee elimination. This reflects a greater level of immunity required in 5-9-year-olds than established previously. The immunity levels we found necessary for measles elimination are higher than previous guidance. The importance of achieving high immunity levels in 5-9-year-olds presents both a challenge and an opportunity. While such high levels can be difficult to achieve, school entry provides an opportunity to ensure sufficient vaccination coverage. Combined with observations of contact patterns, further national and sub-national serological studies could serve to highlight key gaps in immunity that need to be filled in order to achieve national and regional measles elimination.
Sections du résumé
BACKGROUND
Vaccination has reduced the global incidence of measles to the lowest rates in history. However, local interruption of measles virus transmission requires sustained high levels of population immunity that can be challenging to achieve and maintain. The herd immunity threshold for measles is typically stipulated at 90-95%. This figure does not easily translate into age-specific immunity levels required to interrupt transmission. Previous estimates of such levels were based on speculative contact patterns based on historical data from high-income countries. The aim of this study was to determine age-specific immunity levels that would ensure elimination of measles when taking into account empirically observed contact patterns.
METHODS
We combined estimated immunity levels from serological data in 17 countries with studies of age-specific mixing patterns to derive contact-adjusted immunity levels. We then compared these to case data from the 10 years following the seroprevalence studies to establish a contact-adjusted immunity threshold for elimination. We lastly combined a range of hypothetical immunity profiles with contact data from a wide range of socioeconomic and demographic settings to determine whether they would be sufficient for elimination.
RESULTS
We found that contact-adjusted immunity levels were able to predict whether countries would experience outbreaks in the decade following the serological studies in about 70% of countries. The corresponding threshold level of contact-adjusted immunity was found to be 93%, corresponding to an average basic reproduction number of approximately 14. Testing different scenarios of immunity with this threshold level using contact studies from around the world, we found that 95% immunity would have to be achieved by the age of five and maintained across older age groups to guarantee elimination. This reflects a greater level of immunity required in 5-9-year-olds than established previously.
CONCLUSIONS
The immunity levels we found necessary for measles elimination are higher than previous guidance. The importance of achieving high immunity levels in 5-9-year-olds presents both a challenge and an opportunity. While such high levels can be difficult to achieve, school entry provides an opportunity to ensure sufficient vaccination coverage. Combined with observations of contact patterns, further national and sub-national serological studies could serve to highlight key gaps in immunity that need to be filled in order to achieve national and regional measles elimination.
Identifiants
pubmed: 31551070
doi: 10.1186/s12916-019-1413-7
pii: 10.1186/s12916-019-1413-7
pmc: PMC6760101
doi:
Substances chimiques
Measles Vaccine
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Wellcome Trust
ID : 210758/Z/18/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K021680/1
Pays : United Kingdom
Références
Cent Eur J Public Health. 2018 Mar;26(1):22-27
pubmed: 29684293
PLoS One. 2011 Feb 14;6(2):e16965
pubmed: 21347264
Eur J Epidemiol. 2003;18(11):1079-83
pubmed: 14620943
J R Soc Interface. 2010 Jun 6;7(47):873-85
pubmed: 19892718
Science. 2015 May 29;348(6238):958-61, 963
pubmed: 26023116
Comput Math Methods Med. 2011;2011:527610
pubmed: 21860658
J Infect Dis. 2004 May 1;189 Suppl 1:S108-15
pubmed: 15106099
BMC Infect Dis. 2014 Mar 10;14:136
pubmed: 24612900
BMJ Open. 2017 Mar 30;7(3):e014106
pubmed: 28363926
PLoS One. 2017 Jan 18;12(1):e0170459
pubmed: 28099479
J Infect Dis. 2004 May 1;189 Suppl 1:S1-3
pubmed: 15106120
Epidemiol Infect. 2014 May;142(5):1100-8
pubmed: 23915981
Lancet Infect Dis. 2017 Dec;17(12):e420-e428
pubmed: 28757186
N Engl J Med. 1989 Jan 12;320(2):75-81
pubmed: 2911293
Clin Infect Dis. 2011 Apr 1;52(7):911-6
pubmed: 21427399
MMWR Morb Mortal Wkly Rep. 1982 Feb 19;31(6):65-7
pubmed: 6801458
Proc Biol Sci. 2014 Apr 30;281(1785):20140268
pubmed: 24789897
Vaccine. 2009 Jun 19;27(30):3927-34
pubmed: 19376180
Lancet. 2006 Feb 4;367(9508):436-42
pubmed: 16458770
J Infect Dis. 2011 Jul;204 Suppl 1:S1-3
pubmed: 21666150
Proc Biol Sci. 2013 Jun 26;280(1765):20131037
pubmed: 23804621
Epidemiol Infect. 1988 Aug;101(1):1-20
pubmed: 3042433
Vaccine. 2011 Dec 30;29 Suppl 4:D91-6
pubmed: 22185837
Science. 2012 Apr 27;336(6080):406-7
pubmed: 22539695
Vaccine. 2011 Oct 19;29(45):7949-59
pubmed: 21872633
Epidemiol Infect. 2012 Dec;140(12):2117-30
pubmed: 22687447
BMC Infect Dis. 2018 Apr 11;18(1):172
pubmed: 29642869
Biostatistics. 2017 Apr 1;18(2):338-351
pubmed: 28025182
J Infect Dis. 2004 May 1;189 Suppl 1:S27-35
pubmed: 15106086
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
J Infect Dis. 2004 May 1;189 Suppl 1:S4-16
pubmed: 15106083
Vaccine. 2019 Jan 29;37(5):732-741
pubmed: 30579756
Bull World Health Organ. 2008 Mar;86(3):197-204
pubmed: 18368206
J Infect. 2009 Oct;59(4):252-8
pubmed: 19683347
J Hyg (Lond). 1985 Jun;94(3):365-436
pubmed: 4008922
Am J Epidemiol. 2006 Nov 15;164(10):936-44
pubmed: 16968863
PLoS One. 2015 Jul 15;10(7):e0133203
pubmed: 26176549
Lancet Infect Dis. 2017 Oct;17(10):1089-1097
pubmed: 28807627
Lancet. 2016 Aug 13;388(10045):728-30
pubmed: 27059886
Bull World Health Organ. 1998;76 Suppl 2:47-52
pubmed: 10063674
Epidemiol Infect. 2011 Apr;139(4):494-504
pubmed: 20587123
BMC Infect Dis. 2016 Jul 22;16:341
pubmed: 27449511
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Epidemics. 2015 Jun;11:14-23
pubmed: 25979278
J Infect Dis. 2003 May 15;187 Suppl 1:S217-22
pubmed: 12721916